Skip to content

Mutation Detection for VRL

The Diagnostic Value of Mutation Detection for VRL

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05102994
Enrollment
40
Registered
2021-11-02
Start date
2021-11-10
Completion date
2022-06-01
Last updated
2021-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uveitis, Vitreoretinal Lymphoma

Keywords

Vitreoretinal lymphoma, Uveitis, intraocular fluid, mutation

Brief summary

Vitreoretinal lymphoma (VRL) is a rare but aggressive masquerade syndrome, which would be easily confused with uveitis. The diagnostic gold standard remains the pathologic examination of ocular specimen with invasiveness and low sensitivity. To improve the safety and accuracy of VRL diagnosis, alternative techniques using intraocular fluid (IOF) samples are emerging. In this study, we aimed to test the diagnostic value of mutation analysis for VRL

Detailed description

chest CT, urinalysis, kidney, and liver function were routinely checked. IL-10/IL-6 ratio, genetic mutation analysis and samples were IGH gene rearrangements were reviewed and analyzed retrospectively. The diagnoses were identified after careful evaluation of treatment effects in follow-up. The diagnostic value including sensitivity, specificity, positive and negative predictive values, and test efficiency of genetic mutation analysis in diagnosing VRL were analyzed. Furthermore, a validation group of patients including VRL and uveitis was selected to validate the diagnostic value of mutation analysis in the diagnosis of VRL. All the patients signed an informed consent and institutional review board approval was obtained. The study was performed in accordance with the tenets of the Declaration of Helsinki.

Interventions

DIAGNOSTIC_TESTmutation test

detect the tumor-related mutation in introcular fluid

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* suspected VRL patients who had intraocular fluid for mutation test. And got a clear diagnose of VRL or uveitis afther having dianostic tests and follow-up treatment

Exclusion criteria

* suspected VRL patients who lost in follow-up without a definitive diagnose, or whoever reluctance to participate our study

Design outcomes

Primary

MeasureTime frameDescription
the result of mutation testat baseline, before treatmentany mutation detect in intraocular fluild recorded as ctDNA+

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026